Background Atrial fibrillation (AF) is the most prevalent arrhythmia worldwide and the main
cause of anticoagulation, being direct oral anticoagulants (DOAC) increasingly used in this …

Background: Limited clinical data exist describing the use of direct-acting oral
anticoagulants (DOACs) in patients with body mass index (BMI)> 40 kg/m2 or body weight> …

Background Limited clinical data exist describing the use of direct oral anticoagulants
(DOACs) in patient with extreme body weight. Thus, the International Society of Thrombosis …

Background: Due to limited enrollment in landmark trials of patients with a BMI> 30 or
weight> 100 kg for apixaban and rivaroxaban, the International Society of Thrombosis and …

Anticoagulation with direct-acting oral anticoagulants (DOACs) is recommended over
warfarin for stroke prevention in patients with atrial fibrillation (AF). The efficacy of DOACs …

Abstract Background/Introduction The prevalence of obesity has increased in recent
decades and, considering its association with a higher risk of Venous Thromboembolism …

Obesity is a worldwide health problem at increasing incidence associated with high
morbidity and mortality. Although obesity increases patients' cardiovascular (CV) risk, more …

Introduction The clinical outcomes of direct oral anticoagulant (DOAC) dosage regimens in
morbid obesity are uncertain due to limited clinical evidence. This study seeks to bridge this …

Data on the impact of morbid obesity (body mass index [BMI]≥ 40 kg/m2) on the
pharmacokinetics (PK), pharmacodynamics (PD) of direct oral anticoagulants (DOACs) are …

Although nonvitamin K antagonist oral anticoagulants (NOACs) have generally shown
comparable efficacy and better safety compared with warfarin, atrial fibrillation (AF) patients …